Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202505392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Rajesh Mukthavaram und 22 weiteren Autor:innen. Beteiligte Einrichtung: Arcturus Therapeutics Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Lipids, Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Polyethylene glycol (PEG) is a proven component in lipid nanoparticles (LNPs). PEGylated nanoparticles are known to improve LNP circulation half‐life and opsonization profiles. However, the drawbacks of PEG are hypersensitivity reactions due to pre‐existing PEG antibodies and poor biodegradability. These factors warrant a search for alternatives. Some large peptides have shown potent stealth properties in protein delivery. Here, we demonstrate that repeating units of serine‐threonine‐glutamic acid‐proline (STEP) peptide conjugated to dimyristoylglycerol (DMG‐STEP) and incorporated into lipid nanoparticles can perform as functional equivalents of DMG‐PEG. LNPs with DMG‐STEPs displayed similar physicochemical attributes and comparable Factor VII (FVII) silencing and human erythropoietin (hEPO) expression in both mouse and nonhuman primate animal models, with comparable biodistribution profile in mice. Additionally, DMG‐STEP LNPs encapsulating mRNA encoding for SARS‐CoV‐2 Spike protein (Wuhan variant) demonstrated superior humoral immune response in a mouse study. In addition, the preliminary safety of STEP LNPs was demonstrated by quantifying liver enzymes, cytokine induction, complement activation, and anti‐STEP antibody production. Results demonstrated comparable or even reduced cytokine induction responses with STEP LNPs compared to control PEG LNPs. The data presented supports translational potential of STEP LNPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arcturus Therapeutics Inc., San Diego, California, USA.
ORCID-Profile: Kumar Rajappan, Padmanabh Chivukula
Zitieren
APA
Mukthavaram, R., Tanis, S. P., Sagi, A., Parirokh, P., Davis, M., Hong, H., Huynh, H. P., Nguyen, M., Lee, R., Guo, Y., Trelles, R. D., Tachikawa, K., Dam, T., Sablad, M., Acharya, G., Dukanovic, A., Soontornniyomkij, B., Sacchetti, C., Martinez-Redondo, P., …, & Chivukula, P. (2026). Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505392
Vancouver
Mukthavaram R, Tanis SP, Sagi A, Parirokh P, Davis M, Hong H, et al. Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505392
BibTeX
@article{Mukthavaram2026,
author = {Mukthavaram, Rajesh and Tanis, Steven P and Sagi, Amit and Parirokh, Parsa and Davis, Michael and Hong, Hyojung and Huynh, Hannah Pham and Nguyen, Michelle and Lee, Robin and Guo, Yurong and Trelles, Ramon Diaz and Tachikawa, Kiyoshi and Dam, Thanhchau and Sablad, Marciano and Acharya, Grishma and Dukanovic, Adrian and Soontornniyomkij, Benchawanna and Sacchetti, Cristiano and Martinez-Redondo, Paloma and Sullivan, Brian M and Karmali, Priya P and Rajappan, Kumar and Chivukula, Padmanabh},
title = {Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202505392}
}
EUVIMED